Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4+CD25-CD45RA+ naïve T cells to express forkhead box protein 3 and exhibit suppressive ability in vitro

Cancer Science

Volumn 100, Issue 11, 2009, Pages 2143-2151

  Zhao, Xiaofeng ^a   Ye, Feng ^b   Chen, Lili ^b,c   Lu, Weiguo ^b,c   Xie, Xing ^b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b Women's Reproductive Health key Laboratory of Zhejiang Province   (China)

^c Zhejiang University School of Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CD4 ANTIGEN; CD45RA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; LEUKEMIA INHIBITORY FACTOR; NEUTRALIZING ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVATION; CELL CULTURE; CELL SEPARATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPITHELIUM CELL; FEMALE; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPERNATANT; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR LOCALIZATION;

ADULT; CELL LINE, TUMOR; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-10; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; LYMPHOCYTE ACTIVATION; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 71049158433     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01286.x     Document Type: Article

References (55)

1. Peoples GE, Schoof DD, Andrews JV. T-cell recognition of ovarian cancer. Surgery 1993, 114(2):227-34.
2. Ioannides CG, Fisk B, Jerome KR. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993, 151(7):3693-703.
3. Onizuka S, Tawara I, Shimizu J. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59(13):3128-33.
4. Jones E, Dahm-Vicker M, Simon AK. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002, 2:1.
5. Chen L, Huang TG, Meseck M. Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther 2007, 15:2194-202.
6. Dannull J, Su Z, Rizzieri D. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115(12):3623-33.
7. Fu J, Xu D, Liu Z. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132(7):2328-39.
8. Curiel TJ, Coukos G, Zou L. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10(9):942-9.
9. Griffiths RW, Elkord E, Gilham DE. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007, 56(11):1743-53.
10. Hiraoka N, Onozato K, Kosuge T. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006, 12(18):5423-34.
11. Kono K, Kawaida H, Takahashi A. CD4+CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006, 55(9):1064-71.
12. Gao Q, Qiu SJ, Fan J. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25(18):2586-93.
13. Sato E, Olson SH, Ahn J. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102(51):18 538-43.
14. Li X, Ye DF, Xie X. Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest 2005, 23(5):399-403.
15. Woo EY, Chu CS, Goletz TJ. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61(12):4766-72.
16. Liyanage UK, Moore TT, Joo HG. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169(5):2756-61.
17. Ormandy LA, Hillemann T, Wedemeyer H. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005, 65(6):2457-64.
18. Miller AM, Lundberg K, Ozenci V. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006, 177(10):7398-405.
19. Skapenko A, Kalden JR, Lipsky PE. The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. J Immunol 2005, 175(9):6107-16.
20. Chen W, Jin W, Hardegen N. Conversion of peripheral CD4+CD25- naïve T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198(12):1875-86.
21. Fantini MC, Becker C, Monteleone G. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004, 172(9):5149-53.
22. Yamagiwa S, Gray JD, Hashimoto S. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001, 166(12):7282-9.
23. Kretschmer K, Apostolou I, Hawiger D. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005, 6(12):1219-27.
24. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naïve T cells. J Exp Med 2004, 199(10):1401-8.
25. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001, 193(2):F5-9.
26. Jonuleit H, Schmitt E, Schuler G. Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000, 192(9):1213-22.
27. Liu VC, Wong LY, Jang T. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007, 178(5):2883-92.
28. Ghiringhelli F, Puig PE, Roux S. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005, 202(7):919-29.
29. Valzasina B, Piconese S, Guiducci C. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 2006, 66(8):4488-95.
30. Walker MR, Kasprowicz DJ, Gersuk VH. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003, 112(9):1437-43.
31. Walker MR, Carson BD, Nepom GT. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci USA 2005, 102(11):4103-8.
32. Pillai V, Ortega SB, Wang CK. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007, 123(1):18-29.
33. Allan SE, Crome SQ, Crellin NK. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19(4):345-54.
34. Wang J, Ioan-Facsinay A, van der Voort EI. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007, 37(1):129-38.
35. Vukmanovic-Stejic M, Zhang Y, Cook JE. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006, 116(9):2423-33.
36. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-61.
37. Khattri R, Cox T, Yasayko SA. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4:337-42.
38. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-6.
39. Chai JG, Xue SA, Coe D. Regulatory T cells, derived from naïve CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation 2005, 79(10):1310-16.
40. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007, 8(3):277-84.
41. Zhou J, Ye F, Chen H. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 2007, 35(3):290-300.
42. Lambeck AJ, Crijns AP, Leffers N. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007, 13(8):2385-91.
43. Chen LL, Ye F, Lü WG. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J Obstet Gynaecol Res 2009, 35(2):212-18.
44. Metcalfe SM, Watson TJ, Shurey S. Leukemia inhibitory factor is linked to regulatory transplantation tolerance. Transplantation 2005, 79(6):726-30.
45. Zenclussen AC. Regulatory T cells in pregnancy. Springer Semin Immunopathol 2006, 28(1):31-9.
46. Bettelli E, Carrier Y, Gao W. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441(7090):235-8.
47. Oswald-Richter K, Grill SM, Shariat N. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol 2004, 2(7):E198.
48. Yagi H, Nomura T, Nakamura K. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004, 16(11):1643-56.
49. Kim JY, Kim HJ, Hurt EM. Functional and genomic analyses of FOXP3-transduced Jurkat-T cells as regulatory T (Treg)-like cells. Biochem Biophys Res Commun 2007, 362(1):44-50.
50. Bennett CL, Christie J, Ramsdell F. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27(1):20-1.
51. Kobayashi I, Shiari R, Yamada M. Novel mutations of FOXP3 in two Japanese patients with immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX). J Med Genet 2001, 38(12):874-6.
52. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naïve human CD4+FOXP3- T cells by T-cell receptor stimulation is transforming growth factor-β-dependent but does not confer a regulatory phenotype. Blood 2007, 110(8):2983-90.
53. Zheng SG, Wang JH, Gray JD. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004, 172(9):5213-21.
54. Zheng SG, Gray JD, Ohtsuka K. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. J Immunol 2002, 169(8):4183-9.
55. Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-β. J Immunol 2005, 174(3):1446-55.